Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study)
Introduction A substantial proportion of individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), report persisting symptoms weeks and months following acute infection. Estimates on prevalence vary due to differences in study designs, populations, heterogeneity of symp...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/7/e062439.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576245096775680 |
|---|---|
| author | Lotte Haverman Eelco Franz Ka Yin Leung Albert Jan Van Hoek Hans Knoop Cees C van den Wijngaard Elizabeth N Mutubuki Tessa van der Maaden Albert Wong Anna D Tulen Siméon de Bruijn |
| author_facet | Lotte Haverman Eelco Franz Ka Yin Leung Albert Jan Van Hoek Hans Knoop Cees C van den Wijngaard Elizabeth N Mutubuki Tessa van der Maaden Albert Wong Anna D Tulen Siméon de Bruijn |
| author_sort | Lotte Haverman |
| collection | DOAJ |
| description | Introduction A substantial proportion of individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), report persisting symptoms weeks and months following acute infection. Estimates on prevalence vary due to differences in study designs, populations, heterogeneity of symptoms and the way symptoms are measured. Common symptoms include fatigue, cognitive impairment and dyspnoea. However, knowledge regarding the nature and risk factors for developing persisting symptoms is still limited. Hence, in this study, we aim to determine the prevalence, severity, risk factors and impact on quality of life of persisting symptoms in the first year following acute SARS-CoV-2 infection.Methods and analysis The LongCOVID-study is both a prospective and retrospective cohort study being conducted in the Netherlands, with a one year follow-up. Participants aged 5 years and above, with self-reported positive or negative tests for SARS-CoV-2 will be included in the study. The primary outcome is the prevalence and severity of persistent symptoms in participants that tested positive for SARS-CoV-2 compared with controls. Symptom severity will be assessed for fatigue (Checklist Individual Strength (CIS subscale fatigue severity)), pain (Rand-36/SF-36 subscale bodily pain), dyspnoea (Medical Research Council (mMRC)) and cognitive impairment (Cognitive Failure Questionnaire (CFQ)). Secondary outcomes include effect of vaccination prior to infection on persistent symptoms, loss of health-related quality of life (HRQoL) and risk factors for persisting symptoms following infection with SARS-CoV-2.Ethics and dissemination The Utrecht Medical Ethics Committee (METC) declared in February 2021 that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study (METC protocol number 21-124/C). Informed consent is required prior to participation in the study. Results of this study will be submitted for publication in a peer-reviewed journal. |
| format | Article |
| id | doaj-art-6bdf18a32ca4491cabe52ec783a81b06 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-6bdf18a32ca4491cabe52ec783a81b062025-01-31T08:35:08ZengBMJ Publishing GroupBMJ Open2044-60552022-07-0112710.1136/bmjopen-2022-062439Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study)Lotte Haverman0Eelco Franz1Ka Yin Leung2Albert Jan Van Hoek3Hans Knoop4Cees C van den Wijngaard5Elizabeth N Mutubuki6Tessa van der Maaden7Albert Wong8Anna D Tulen9Siméon de Bruijn10Child and Adolescent Psychiatry and Psychological Care, Emma Children’s Hospital, Amsterdam Reproduction and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsNational Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, Bilthoven, The NetherlandsNational Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, Bilthoven, The NetherlandsNational Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, Bilthoven, The NetherlandsDepartment of Medical Psychology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, the NetherlandsCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The NetherlandsNational Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, Bilthoven, The NetherlandsCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The NetherlandsVancouver, BC, CanadaNational Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, Bilthoven, The NetherlandsNational Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, Bilthoven, The NetherlandsIntroduction A substantial proportion of individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), report persisting symptoms weeks and months following acute infection. Estimates on prevalence vary due to differences in study designs, populations, heterogeneity of symptoms and the way symptoms are measured. Common symptoms include fatigue, cognitive impairment and dyspnoea. However, knowledge regarding the nature and risk factors for developing persisting symptoms is still limited. Hence, in this study, we aim to determine the prevalence, severity, risk factors and impact on quality of life of persisting symptoms in the first year following acute SARS-CoV-2 infection.Methods and analysis The LongCOVID-study is both a prospective and retrospective cohort study being conducted in the Netherlands, with a one year follow-up. Participants aged 5 years and above, with self-reported positive or negative tests for SARS-CoV-2 will be included in the study. The primary outcome is the prevalence and severity of persistent symptoms in participants that tested positive for SARS-CoV-2 compared with controls. Symptom severity will be assessed for fatigue (Checklist Individual Strength (CIS subscale fatigue severity)), pain (Rand-36/SF-36 subscale bodily pain), dyspnoea (Medical Research Council (mMRC)) and cognitive impairment (Cognitive Failure Questionnaire (CFQ)). Secondary outcomes include effect of vaccination prior to infection on persistent symptoms, loss of health-related quality of life (HRQoL) and risk factors for persisting symptoms following infection with SARS-CoV-2.Ethics and dissemination The Utrecht Medical Ethics Committee (METC) declared in February 2021 that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study (METC protocol number 21-124/C). Informed consent is required prior to participation in the study. Results of this study will be submitted for publication in a peer-reviewed journal.https://bmjopen.bmj.com/content/12/7/e062439.full |
| spellingShingle | Lotte Haverman Eelco Franz Ka Yin Leung Albert Jan Van Hoek Hans Knoop Cees C van den Wijngaard Elizabeth N Mutubuki Tessa van der Maaden Albert Wong Anna D Tulen Siméon de Bruijn Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) BMJ Open |
| title | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
| title_full | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
| title_fullStr | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
| title_full_unstemmed | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
| title_short | Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) |
| title_sort | prevalence and determinants of persistent symptoms after infection with sars cov 2 protocol for an observational cohort study longcovid study |
| url | https://bmjopen.bmj.com/content/12/7/e062439.full |
| work_keys_str_mv | AT lottehaverman prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT eelcofranz prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT kayinleung prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT albertjanvanhoek prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT hansknoop prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT ceescvandenwijngaard prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT elizabethnmutubuki prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT tessavandermaaden prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT albertwong prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT annadtulen prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy AT simeondebruijn prevalenceanddeterminantsofpersistentsymptomsafterinfectionwithsarscov2protocolforanobservationalcohortstudylongcovidstudy |